CD4 and myeloid sarcoma: Substantial heterogeneity was noted in MS prevalence by CD4 count levels within studies that applied the ATPIII-2001 and ATPIII-2004-2005 criteria (all p-heterogeneity≤0.035) but not within studies that used the IDF-2005 definition (p-heterogeneity≥0.272).